ORAMED PHARMACEUTICALS INC.
ORMP · XNASCIK 1176309fmd_1FGZEF4H659JXBPA4T1CR2A3GG制造业 · 医药制剂模板: 标准
覆盖范围: 2007年9月01日 至 2026年9月30日，共 71 个期间
| 项目 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | 1 | 2 | 2 | 3 | 3 | 3 | 3 | 1 | – | 2 |
| 营业成本 | 0 | 0 | (0) | 0 | – | – | – | – | – | 2 |
| 交易及自营业务收入 | – | – | – | – | – | – | – | 5 | – | – |
| 毛利润 | 0 | 2 | 3 | 3 | – | – | – | – | – | 0 |
| 研发费用 | 8 | 10 | 12 | 14 | 10 | 21 | 28 | 9 | 6 | 6 |
| 营业利润 | (10) | (11) | (14) | (15) | (12) | (24) | (41) | (16) | (13) | (15) |
| 利息费用 | – | – | – | – | – | – | – | 2 | 1 | – |
| 利息及投资收益 | – | – | – | – | – | – | – | 0 | – | – |
| 其他营业外收入（支出） | – | – | – | – | – | – | 3 | 23 | (2) | 89 |
| 税前利润 | (10) | (10) | (13) | (14) | (12) | 23 | (38) | 5 | (16) | 75 |
| 所得税费用 | 1 | 0 | – | 0 | – | – | 0 | – | 3 | 11 |
| 持续经营净利润 | (11) | (10) | – | (14) | – | – | 0 | – | (19) | 64 |
| 净利润 | (11) | (10) | (13) | (14) | (12) | (23) | (37) | 5 | (19) | 64 |
| 归属于普通股股东的净利润 | – | – | – | – | 12 | 23 | (37) | – | (19) | 63 |